Amgen broadens multispecifics tool kit with $900M TeneoBio takeout

As multispecific therapies continue to gain traction, Amgen is building out its tool kit through its acquisition of TeneoBio for $900 million up front and $1.6 billion in milestones. 

Amgen Inc. (NASDAQ:AMGN) is playing catch-up in dominant areas of immuno-oncology such as checkpoint inhibitors and CAR Ts, but it has a first-mover advantage when it comes to bispecifics. It has been pouring resources into bispecifics and multispecifics in a bid to maintain its lead. ...